SRSawsan A. Abdel Razek

Sawsan A. Abdel Razek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sawsan A. Abdel Razek has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid micellar HPLC analysis of loratadine and its major metabolite desloratadine in nano-concentration range using monolithic column and fluorometric detection: application to pharmaceuticals and biological fluids

    by Fathalla Belal, Sawsan Abd El-Razeq, Mohamed El-Awady, Sahar Zayed, Sona Barghash

    Loratadine is a commonly used selective non-sedating antihistaminic drug. Desloratadine is the active metabolite of loratadine and, in addition, a potential impurity in loratadine bulk powder stated by the United States Pharmacopeia as a related substance of loratadine. Published methods for the determination of both analytes suffer from limited throughput due to the time-consuming steps and tedious extraction procedures needed for the analysis of biological samples. Therefore, there is a strong demand to develop a simple rapid and sensitive analytical method that can detect and quantitate both analytes in pharmaceutical preparations and biological fluids without prior sample extraction steps. A highly-sensitive and time-saving micellar liquid chromatographic method is developed for the simultaneous determination of loratadine and desloratadine. The proposed method is the first analytical method for the determination of this mixture using a monolithic column with a mobile phase composed of 0.15 M sodium dodecyl sulfate, 10% n-Butanol and 0.3% triethylamine in 0.02 M phosphoric acid, adjusted to pH 3.5 and pumped at a flow rate of 1.2 mL/min. The eluted analytes are monitored with fluorescence detection at 440 nm after excitation at 280 nm. The developed method is linear over the concentration range of 20.0–200.0 ng/mL for both analytes. The method detection limits are 15.0 and 13.0 ng/mL and the limits of quantification are 20.0 and 18.0 ng/mL for loratadine and desloratadine, respectively. Validation of the developed method reveals an accuracy of higher than 97% and intra- and inter-day precisions with relative standard deviations not exceeding 2%. The method can be successfully applied to the determination of both analytes in various matrices including pharmaceutical preparations, human urine, plasma and breast milk samples with a run-time of less than 5 min and without prior extraction procedures. The method is ideally suited for use in quality control laboratories. Moreover, it could be a simple time-saving alternative to the official pharmacopeial method for testing desloratadine as a potential impurity in loratadine bulk powder.


  • Open Access

    Pharmaceutical and Analytical Evaluation of Prolonged Release Rosuvastatin-Ca Buccoadhesive Tablets

    by Maha A. Marzouk, Sawsan A. Abdel-Razeq, Marwa M. Soliman

    Rosuvastatin-Ca was prepared in solid dispersion as buccoadhesive tablets to increase its bioavailability and the release of the drug from its buccoadhesive formulae due to its poor aqueous solubility. The solid dispersions were prepared using β-cyclodextrin, polyethylene glycol 6000 and polyethylene glycol 4000 by kneading and solvent evaporation methods and were characterized by differential scanning calorimetry (DSC). They were also prepared using poloxamer 407 as a biocompatible and mucoadhesive carrier by freeze drying method. The buccoadhesive tablets of the drug were formulated using sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose and sodium alginate by direct compression method. The prepared tablets were evaluated for their physical, dissolution, mucoadhesive and swelling properties. An in-vitro release study showed slow and prolonged release of the drug from tablets as compared to marketed formulation. Five formulae were selected for applying the recently reported analytical methods and results were compared statistically with a compendial one.

  • Open Access

    Densitometric and Spectrometric Determinations of Florfenicol and Buparvaquone

    by Fathalla F. Belal, Sawsan A. Abdel-Razeq, Manal M. Fouad, Fatma A. Fouad

    Three new accurate and sensitive methods were developed for the determination of two veterinary drugs. Florfenicol was analyzed by a stability-indicating TLC/densitometric method in presence of its amine degradation product obtained via acid hydrolysis. It was based on the difference in Rf values of the drug and its degradation product at 254 nm on silica gel 60 GF254 plates using chloroform–methanol (7:3 v/v) as developing solvent (Method A). However, buparvaquone was analyzed through reduction with NaBH4 in methanolto yielda red colored product measured spectrophotometrically at 489 nm (Method B). This reduction product was also measured spectrofluorometrically at 450 nm after excitation at 334 nm (Method C). Good linearity was obtained in the range of 10-100 µg/spot for florfenicol in method A and 10-120 or 0.3-2.4 µg mL-1 for buparvaquone by methods B and C with mean accuracy of 99.94%±0.89, 99.99%±0.99 or 99.66%±1.80, respectively. The densitometric method A proved to be stability-indicating in presence of 10-90% of buparvaquone amine degradation product. The three proposed methods were validated according to ICH guidelines and successfully applied for the assay of the cited drugs in their pharmaceutical formulations.


  • Open Access

    Development and Validation of Densitometry TLC Stability Indicating Method for Quantitative Determination of Azelastine Hydrochloride and Emedastine Difumarate in Their Drug Products

    by Nahla N. Salama, Sawsan A. Abdel-Razeq, Shimaa Abdel-Atty, Naglaa El-Kosy

    Aims: Stability indicating densitometry-TLC assay was established and validated for determination of azelastine hydrochloride (AZT) and emedastine difumarate (ETD) in the presence of their acid and oxidative degradants. Methodology: Forced degradation was performed using 30% H2O2 and 5 M HCl. The method was based on thin-layer chromatographic separation of the two drugs from their degradants, using methanol- 10% ammonia (9.5:0.5, v/v) as developing system, followed by densitometric measurements of the intact drug spots at 292 and 283 nm, for azelastine hydrochloride and emedastine difumarate respectively. Results: The linear range was 0.5 - 10.0 μg/spot, with mean recoveries of 100.09 ± 0.53% and 100.36 ± 0.40% for azelastine hydrochloride and emedastine difumarate respectively. Conclusion: The proposed method was successfully applied for the routine quality control analysis of both drugs in laboratory prepared mixtures and commercially available preparations. The degradation products were identified by IR and MS and the pathways were illustrated. The method was validated according to ICH.


  • Open Access

    Construction of different types of ion-selective electrodes and validation of direct potentiometric determination of phenytoin sodium

    by Maha El-Tohamy, Sawsan Razeq, Magda El-Maamly, Abdalla Shalaby

    The construction and performance characteristics of phenytoin sodium selective electrodes are detailed. Two types of electrodes: plastic membrane I and coated wire II, were constructed based on the incorporation of phenytoin sodium with tungstosilicic acid. The influence of membrane composition, kind of plasticizer, pH of the test solution, soaking time and the electrodes’ foreign ions were investigated. The electrodes showed a Nernstian response with a mean calibration graph slope of 30.9±0.1 and 28.9±0.1 mV decade−1 at 25°C for electrode I and II respectively, over a phenytoin sodium concentration range of 5×10−3−5×10−6 M and 1×10−3−1×10−6 M with a detection limit 1.3×10−6 M and 2.5×10−7 M for electrode I and II, respectively. The electrodes gave average selective precision and were usable within the pH range 6–10. Interference studies from common cations, alkaloids, sugars, amino acids and drug excipients are reported. The results obtained by the proposed electrodes were also applied successfully for the determination of the drug in pharmaceutical preparations and biological fluids.


    • 1 December 2009
      • Vol. 3  (6) , 247-52

    Stability-indicating methods for the determination of racecadotril in the presence of its degradation products.

    by Afaf O Mohamed, Manal M Fouad, Mona M Hasan, Sawsan A Abdel Razeq, Zeinab A Elsherif

    Three stability-indicating methods were developed for the determination of racecadotril (RCT) in the presence of its alkaline degradation products. The first was an HPLC method in which efficient chromatographic separation was achieved on a C18 analytical column and a mobile phase of acetonitrile-methanol-water-acetic acid (52:28:20:0.1, v/v/v/v). Linearity was obtained in the range of 4-40 microg/mL with mean accuracy of 99.5 +/- 0.88%. The second method was a densitometric evaluation of thin-layer chromatograms of the drug using a mobile phase of isopropanol-ammonia (33%)-n-hexane (9:0.5:20, v/v/v). The chromatograms were scanned at 232 nm, a wavelength at which RCT can be readily separated from its degradation products and determined in the range of 2-20 microg per spot with mean accuracy of 99.5 +/- 0.56%. The third method is based on the use of first-derivative spectrophotometry (D1) at 240 nm, and the drug was determined in the range of 5-40 microg/mL with mean accuracy of 99.2 +/- 1.02%. The three methods provided satisfactory recovery of the intact drug (100.8 +/- 0.82, 100.4 +/- 0.55, and 99.9 +/- 0.72%, respectively) in the presence of up to 90% of its degradation products. Determination was also successful when analyzing RCT in a formulation in the form of acetorphan packets. Results were statistically analyzed and found to be in accordance with those given by a reported method.

  • Open Access

    Voltammetric quantitation at the mercury electrode of the anticholinergic drug flavoxate hydrochloride in bulk and in a pharmaceutical formulation

    by M.M. Ghoneim, M.A. El-Attar, S.A. Razeq

    Flavoxate hydrochloride, 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4-H-chromene-8-carboxylate, is a smooth muscle antispasmodic. Its electrochemical behavior was studied at the mercury electrode in buffered solutions containing 30% (v/v) methanol using dc-polarography, differential-pulse polarography, cyclic voltammetry, and linear sweep-and square-wave adsorptive stripping voltammetry. Sensitive and precise procedures were developed for determination of bulk flavoxate hydrochloride and in the pharmaceutical formulation Genurin® S.F, without sample pretreatment or extraction. Limits of quantitation (LOQ) of 1 × 10−5, 5 × 10−6, 1 × 10−8 and 1 × 10−9 M flavoxate hydrochloride were achieved by dc-polarography, differential-pulse polarography, linear sweep and square-wave adsorptive stripping voltammetric, respectively.